{
    "symbol": "PASG",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-10 10:26:10",
    "content": " Before we begin, please note that today's call may include a number of forward-looking statements including, but not limited to, comments on our expectations about timing and execution of anticipated milestones, including the initiation of clinical trials and the availability of clinical data from such trials; our expectations about our collaborators and partners' ability to execute key initiatives; the ability of our lead product candidates to treat their respective target CNS disorder; manufacturing plans and strategies; our expectations with respect to cash runway and trends with respect to financial performance and cash flows; the company's ability to fund research and development programs; impact of the COVID-19 pandemic on the company's operations; and its ability to manage costs along with uses of cash and other matters. As we move into 2023 and the data from our clinical programs matures, we look forward to aligning on the registrational pathway for GM1 and continuing to enroll additional patients in our upliFT-D trial. Your line is open. One moment for our next question. Your line is open. So, thanks for the question. One moment for our next question. Your line is open. So, thanks for the question. One moment for our next question. Your line is open. So, for all of the patients currently, -- for the entire -- the FTD trial, the first this PBFT0 protocol one, there is a 60-day waiting period for all patients as we enroll the trial, both in cohort 1 and higher dose cohorts, we believe that's important as we need to establish safety at the higher doses as we escalate. One moment for our next question. Your line is open. One moment for our next question. Your line is open. One moment for our next question. Your line is open. So, thanks for the question."
}